Non-invasive Prenatal Testing (NIPT) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Consumables, Instruments), By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others), By Application (Trisomy, Microdeletion Syndrome, Others), By End User (Diagnostic Laboratories, Hospitals, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Non-invasive Prenatal Testing (NIPT) Market was valued at USD 5.03 Billion in 2024 and is expected to reach USD 7.74 Billion by 2030 with a CAGR of 7.42%. The Global Non-invasive Prenatal Testing (NIPT) Market is experiencing notable growth due to increasing awareness of genetic conditions and the growing demand for safer prenatal testing methods. Rising maternal age has contributed to a higher incidence of chromosomal abnormalities, prompting more expectant parents to opt for non-invasive screening techniques. NIPT offers a safer alternative to traditional invasive procedures like amniocentesis, reducing the risk of miscarriage while delivering accurate results. Favorable government initiatives supporting early diagnosis, coupled with the expansion of private healthcare services, are also propelling the adoption of NIPT across various segments of the population. The convenience of sample collection through simple blood tests and faster turnaround times are further enhancing patient acceptance.

Key trends shaping the market include the integration of advanced genomic technologies and the use of artificial intelligence in test analysis to improve diagnostic accuracy. The increasing shift toward personalized medicine is supporting the evolution of NIPT offerings to screen for a broader spectrum of genetic conditions beyond common trisomies. Companies are also investing in the development of multiplex assays capable of detecting multiple disorders from a single sample. The rise in partnerships between diagnostic companies and hospitals is streamlining access to NIPT services. Consumer demand for at-home sample collection services is on the rise, pushing providers to offer more flexible and patient-centric testing options.

Despite positive momentum, the market faces several challenges. Variability in reimbursement policies across different countries creates disparities in accessibility, limiting the market potential in certain regions. Ethical concerns regarding prenatal genetic screening, especially in cases of expanded panels detecting non-medical traits, continue to spark debate. A lack of standardized regulatory guidelines for newer tests and emerging providers may also lead to inconsistent quality and reliability. Limited access to advanced diagnostic technologies in public healthcare settings and insufficient genetic counseling services further hinder comprehensive adoption of NIPT across all socioeconomic groups.

Rising Maternal Age and Associated Risk of Chromosomal Abnormalities

The rising maternal age in Europe is one of the key drivers of the Non-Invasive Prenatal Testing (NIPT) market. As societal trends shift, many women are choosing to have children later in life due to factors such as career development, financial stability, and lifestyle preferences. According to recent data from the Office for National Statistics (ONS), the average age of mothers at childbirth in England and Wales reached 30.9 years in 2023, continuing a gradual increase over the years. This delay in childbirth corresponds to an increased risk of chromosomal abnormalities, including Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). These conditions are more prevalent among pregnancies in women of advanced maternal age, particularly those aged 35 and older.

NIPT is becoming the go-to method for prenatal screening because it is non-invasive, highly accurate, and carries no risk of miscarriage, unlike traditional invasive tests like amniocentesis or chorionic villus sampling (CVS). The test uses a blood sample from the mother to analyze cell-free fetal DNA, making it a safer option for both the mother and the fetus. As a result, NIPT is increasingly preferred by expectant mothers, especially those in higher age brackets.

In the UK, NIPT has been integrated into routine prenatal care, supported by the National Health Service (NHS), further increasing its accessibility. The growing maternal age in Europe means that more women are seeking non-invasive, reliable prenatal screening options to assess the risk of chromosomal abnormalities, driving the demand for NIPT. As these trends continue, the market for NIPT is expected to expand significantly, making it a standard part of prenatal care in the coming years.

Availability of Advanced Screening Technologies

Advancements in genome sequencing technologies have led to reduced turnaround time and simplified diagnosis through next-generation sequencing (NGS). The utilization of NGS technology presents numerous opportunities for the development of non-invasive diagnostic procedures, enabling early and precise detection of various genetic disorders. The life science industry is currently experiencing significant growth in NGS-based NIPT tests, as several biotechnology companies are actively engaged in researching and developing such products. Moreover, the integration of genome sequencing technologies in the life science industry has empowered companies to detect genetic diseases at an early stage, delivering accurate results to maintain competitiveness in the market. Advances in DNA sequencing technology have significantly improved the accuracy and reliability of NIPT. This has further bolstered its appeal among healthcare providers and patients alike. Advanced screening technologies, such as Next-Generation Sequencing (NGS), have significantly improved the accuracy and reliability of NIPT results. NGS allows for the detection of fetal genetic material in the maternal bloodstream with high precision, leading to more reliable screening outcomes. As advanced technologies improve the sensitivity of NIPT, the test can now detect a broader range of genetic conditions beyond chromosomal trisomies. This expanded scope, which includes sex chromosome aneuploidies and microdeletion syndromes, makes NIPT even more attractive to expectant parents seeking comprehensive information about their baby's health. With advanced screening technologies, NIPT can identify genetic abnormalities at an earlier stage of pregnancy. This early detection allows parents and healthcare providers to make timely and informed decisions about medical interventions and care plans. Advanced technologies have contributed to a decrease in the rate of false-positive results in NIPT. This reduction helps alleviate unnecessary stress and anxiety for expectant parents and minimizes the need for follow-up invasive procedures.

Favorable Regulatory Environment and Government Initiatives

​A favorable regulatory environment and proactive government initiatives are significantly propelling the growth of the Global Non-invasive Prenatal Testing (NIPT) Market. European healthcare authorities are increasingly recognizing the clinical value and cost-effectiveness of early genetic screening, prompting several countries to include NIPT in their public healthcare offerings. Governments are actively integrating NIPT into national prenatal screening programs to improve pregnancy outcomes and reduce the need for invasive diagnostic procedures. In countries like the Netherlands and Belgium, NIPT has been adopted as a first-tier screening option, fully or partially reimbursed by national health systems. These policies not only expand access to expectant mothers but also signal strong institutional support for innovation in prenatal care.​

Regulatory agencies such as the European Medicines Agency (EMA) and country-specific health technology assessment (HTA) bodies are increasingly working to streamline approval processes for NIPT technologies, which encourages new entrants and promotes healthy market competition. In 2024, the EMA recommended 114 medicines for marketing authorization, with 46 containing new active substances, reflecting a commitment to facilitating innovative healthcare solutions. Initiatives promoting precision medicine and maternal health, often backed by EU-level research funding, have created a favorable climate for companies investing in advanced prenatal diagnostics. The emphasis on early intervention and prevention in national health policies has led to increased budget allocations for prenatal care. These efforts ensure that NIPT becomes more accessible and standardized across the continent, driving demand in both public and private healthcare sectors.​

Increasing Prevalence of Genetic and Congenital Disorders

​The increasing prevalence of genetic and congenital disorders is significantly driving the demand for Non-Invasive Prenatal Testing (NIPT) in India. As awareness of these conditions grows and their impact on families becomes more apparent, expectant parents are seeking methods to ensure the health and well-being of their unborn children. NIPT offers a non-invasive and accurate method for early detection of certain genetic abnormalities, making it an attractive option for those at higher risk.​

Recent data underscores this trend. A meta-analysis by Bhide and Kar reported a pooled prevalence rate of 184.48 congenital anomalies per 10,000 live births in India. Additionally, a systematic review and meta-analysis found the prevalence of neural tube defects (NTDs) in India to be 9.46 per 1,000 births. These statistics highlight the substantial burden of genetic disorders in the country.​

As medical advancements enable early detection of genetic disorders, parents are recognizing the value of early intervention and medical planning. NIPT provides information that allows parents and healthcare providers to make informed decisions about pregnancy management and future care. The rising prevalence of genetic and congenital disorders has led to heightened awareness and concern among expectant parents. This, in turn, has driven the demand for accurate and non-invasive prenatal screening options like NIPT. As the medical community continues to emphasize the importance of early detection and intervention, NIPT is likely to remain a sought-after tool for assessing the genetic health of unborn children.​

Download Free Sample Report

Key Market Challenges

Limitations of NIPT

Although NIPT is highly accurate, there is still a possibility of false-positive or false-negative results. False positives can lead to unnecessary anxiety and additional invasive testing, while false negatives might provide a false sense of security. These uncertainties can make some patients hesitant to fully rely on NIPT. NIPT is a screening test, not a diagnostic one. Positive NIPT results require confirmation through invasive diagnostic tests like amniocentesis or CVS. The need for follow-up invasive procedures can deter some individuals from pursuing NIPT. NIPT mainly focuses on chromosomal abnormalities and may not provide insight into functional genetic disorders or certain rare conditions. This limitation can be frustrating for parents seeking a comprehensive understanding of their baby's health. While the cost of NIPT has decreased over time, it can still be relatively expensive, especially for individuals without insurance coverage. Cost considerations may lead some people to explore alternative screening methods or forgo genetic testing altogether. NIPT's accuracy for detecting rare genetic conditions or those caused by de novo mutations may not be as high as for common aneuploidies. This uncertainty can affect decisions for families with specific genetic concerns.

Alternative Screening and Testing Methods

Traditional serum screening tests, like the first trimester combined test (which includes ultrasound and blood tests), have been used for years to assess the risk of chromosomal abnormalities. Some individuals may opt for these tests due to familiarity or recommendations from healthcare providers, despite the fact that NIPT offers higher accuracy and earlier detection. Sequential screening involves combining first-trimester serum screening with second-trimester maternal serum markers. While this approach provides more information than traditional screening alone, it might still be less accurate than NIPT for certain conditions. Some patients might choose this route over NIPT due to a lack of awareness about the benefits of NIPT. Some individuals might prefer invasive diagnostic tests like amniocentesis or chorionic villus sampling (CVS) over NIPT, even though they carry a small risk of miscarriage. This could be due to concerns about the accuracy of NIPT, a desire for a definitive diagnosis, or personal beliefs.

Key Market Trends

Availability of Direct-to-Consumer Tests

The availability of Direct-to-Consumer (DTC) tests for Non-Invasive Prenatal Testing (NIPT) has the potential to significantly boost its demand in the future. DTC testing allows individuals to access genetic testing services without involving a healthcare provider as an intermediary. While there are both advantages and concerns associated with DTC testing, it can play a role in increasing awareness, accessibility, and utilization of NIPT.  DTC testing eliminates the need for a healthcare provider's referral or prescription. This can make NIPT more accessible to individuals who might not have easy access to medical facilities or who prefer a more convenient testing process. DTC NIPT can encourage individuals to consider early genetic screening, even before consulting with a healthcare provider. This emphasis on early detection aligns with the current trend of proactive healthcare management. DTC testing allows individuals to make their own decisions about genetic testing, potentially leading to more proactive and informed choices about prenatal care.

Integration of NIPT into Routine Prenatal Care

The integration of non-invasive prenatal testing (NIPT) into routine prenatal care is a significant trend in the European healthcare landscape. This shift is driven by advancements in genomic technologies and a growing emphasis on personalized medicine, leading to the widespread adoption of NIPT as a standard screening option during pregnancy. Healthcare systems across Europe are increasingly incorporating NIPT into standard prenatal care protocols. This integration is facilitated by the test's high accuracy in detecting common chromosomal abnormalities such as trisomy 21, 18, and 13, and its non-invasive nature, which poses no risk to the fetus. Clinicians are now recommending NIPT earlier in the screening process, often as a first-line test rather than a secondary confirmatory tool, particularly for women of advanced maternal age or those with elevated risk pregnancies.​

The alignment of NIPT with national healthcare protocols and insurance coverage frameworks is enhancing its accessibility and acceptance. In countries like the Netherlands and Belgium, NIPT is government-funded and offered as a first-tier screening option for all pregnant women. This approach has led to high uptake rates, with studies indicating that in regions like Andalucía, Spain, the uptake of second-line NIPT reached 93.2% among eligible pregnancies. Integration into routine practice also promotes improved patient education and engagement, as expectant mothers receive counseling on test availability, benefits, and limitations during early antenatal visits. The development of automated platforms and user-friendly reporting systems is streamlining clinical workflows and reducing administrative burdens for healthcare professionals.​

As a result, the inclusion of NIPT in standard prenatal care is transforming the patient experience and shaping the future of maternal-fetal medicine by promoting early, accurate, and equitable access to critical genetic information. 

Segmental Insights

Product Type Insights

Based on the Product Type, Consumables emerged as the dominant segment in the Global Non-invasive Prenatal Testing (NIPT) Market in 2024. This segment includes key components like blood collection kits, reagents, test panels, and other materials used in the execution of NIPT. The increasing demand for NIPT services has directly contributed to the growth of the consumables segment. Consumables are essential for conducting NIPT as they ensure the efficient and accurate collection, processing, and analysis of maternal blood samples for genetic screening. As the adoption of NIPT expands across Europe, the volume of consumables required for these tests continues to rise, making it the dominant segment. The dominance of consumables can be attributed to the regular usage of these products for each test, resulting in consistent demand. Moreover, the growing emphasis on expanding testing options to include more genetic disorders has driven the need for diverse consumable products. The integration of more advanced technologies, such as next-generation sequencing (NGS), into NIPT has also contributed to the increased need for high-quality consumables.

Test Type Insights

Based on the Test Type, NIFTY emerged as the dominant segment in the Global Non-invasive Prenatal Testing (NIPT) Market in 2024. NIFTY, a brand of non-invasive prenatal testing, is widely recognized for its accuracy in detecting chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome. This test is based on analyzing cell-free DNA from maternal blood, offering a non-invasive, highly accurate alternative to traditional invasive prenatal diagnostic methods like amniocentesis or chorionic villus sampling. The dominance of NIFTY in the market can be attributed to its comprehensive testing panel and its high accuracy rates. NIFTY is trusted by healthcare providers and expectant parents alike due to its reliable results and minimal risk to the pregnancy. As more healthcare professionals adopt NIFTY as a standard screening tool, its popularity continues to grow in Europe, driving its position as the leading test type in the NIPT market.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Non-Invasive Prenatal Testing (NIPT) Market in 2024 due to the widespread adoption of advanced diagnostic technologies, high awareness levels among expectant parents, and strong healthcare infrastructure. The region benefits from a robust regulatory environment and well-established clinical guidelines that support the use of NIPT as a standard screening tool, particularly for high-risk pregnancies. Additionally, the presence of leading NIPT providers and diagnostic companies across the United States and Canada has significantly contributed to the market’s growth by driving innovation, accessibility, and affordability of testing solutions. The high prevalence of chromosomal abnormalities, coupled with increasing maternal age, has also boosted demand for early and accurate prenatal screening options. Public and private health insurers in North America have progressively expanded coverage for NIPT, further encouraging adoption. Moreover, collaborations between biotech firms and research institutions in the region have accelerated the development and validation of newer, more comprehensive NIPT panels.

Asia-Pacific has emerged as the fastest growing region in the Global Non-Invasive Prenatal Testing (NIPT) Market during the forecast period due to increasing healthcare expenditure, a rising middle-class population, and greater access to advanced maternal healthcare services. The region is witnessing a surge in demand for preventive and personalized medicine, with expectant parents showing increased interest in early and non-invasive diagnostic options. Rapid urbanization and improved literacy levels have significantly enhanced public awareness about genetic and congenital disorders, encouraging more pregnant women to opt for prenatal screening. Countries like China, India, and South Korea are seeing a growing acceptance of NIPT, driven by government-led healthcare reforms, expansion of diagnostic laboratories, and the incorporation of genomic medicine into national health programs.

Recent Developments

• In April 2025, Kuon Healthcare, a UK-based diagnostic provider, announced the expansion of its blood testing services to enhance accessibility through both clinic-based and home testing options. The company offers a broad range of tests, including non-invasive prenatal testing (NIPT), hormone and vitamin assessments, menopause screening, and sports performance analysis. Partnering with UKAS-accredited labs, Kuon aims to deliver fast, accurate, and patient-centered diagnostics across the UK.
• In December 2024, precision diagnostics firm BillionToOne announced that its UNITY Non-Invasive Prenatal Test (NIPT) for fetal antigens is now being used by Maternal-Fetal Medicine (MFM) with limited maternity care access. Designed for alloimmunized patients, the test helps detect risk of hemolytic disease of the fetus and newborn (HDFN) by identifying specific genetic variations. The adoption of UNITY NIPT has improved prenatal care in underserved regions by reducing the need for repeated in-person follow-ups, offering more accessible, high-quality maternal healthcare for remote populations.
• In May 2024, digital health company Igentify launched new Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) solutions through its Digital Genetic Assistant platform. The offering streamlines patient intake via a web app featuring ACOG-compliant consent and personalized educational videos. Clinicians benefit from tools enabling rapid triage and low-risk result delivery, including optional fetal sex disclosure. These additions complement Igentify’s existing Expanded Carrier Screening (ECS) services.
• In April 2024, Strand Life Sciences, a subsidiary of Reliance Industries Ltd., launched its prenatal screening and diagnostics portfolio featuring two advanced technologies: CNSeq for detecting aneuploidies and copy number variations, and MaatriSeq for non-invasive prenatal screening. The company stated that these solutions are designed for the Indian population, focusing on high accuracy, efficiency, and affordability.
• In March 2024, molecular diagnostics firm BillionToOne launched BabyPeek, a non-invasive prenatal genetic test. Using maternal blood and cell-free DNA sequencing, the test predicts ten non-medical baby traits, including eye and hair color, freckle likelihood, food preferences, and timing of first tooth. Designed for light-hearted use during pregnancy, BabyPeek is available as an optional add-on to BillionToOne’s existing Unity prenatal test.

Key Market Players

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

            ·         Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

o   Consumables

o   Instruments

            ·         Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

o   Materni 21

o   Harmony

o   Panaroma

o   Verifi

o   NIFTY

o   Others

            ·         Non-invasive Prenatal Testing (NIPT) Market, By Method:

o   Ultrasound Detection

o   Biochemical Screening Testing

o   Cell-Free DNA Maternal Plasma Tests

o   Fetal Cells in Maternal Blood Tests

o   Others

            ·         Non-invasive Prenatal Testing (NIPT) Market, By Application:

o   Trisomy

o   Microdeletion Syndrome

o   Others

            ·         Non-invasive Prenatal Testing (NIPT) Market, By End User:

o   Diagnostic Laboratories

o   Hospitals

o   Others

            ·         Non-invasive Prenatal Testing (NIPT) Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Non-invasive Prenatal Testing (NIPT) Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com